# The association between major depressive disorder and cannabis use disorder: A meta-analysis and meta-regression analysis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/major-depressive-disorder-cannabis-use-meta-analysis/ > **Published:** 2026-03-24T17:10:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:08:42-04:00 > **Clinical Summary:** Explore the meta-analysis on major depressive disorder cannabis use meta-analysis revealing key prevalence and clinical insights for integrated treatment approaches. --- CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Depression[Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)ComorbidityMeta-AnalysisScreening Journal Journal of psychiatric research Study Type Meta-Analysis Population Human participants Why This Matters This meta-analysis provides robust prevalence data on the bidirectional relationship between major depressive disorder and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder, informing screening protocols and integrated treatment approaches. Understanding these co-occurrence rates is essential for clinicians managing either condition, as untreated comorbidity significantly impacts treatment outcomes. Clinical Summary This systematic review and meta-analysis of 55 studies encompassing over 3.2 million individuals examined current-diagnosis prevalence rates of MDD among patients with CUD and vice versa. The analysis differentiated between psychiatric and community samples and employed rigorous methodology including sensitivity analyses and assessment for publication bias. Results demonstrated elevated prevalence of MDD among individuals with CUD in both clinical and community settings, though the summary appears truncated in the available abstract. The study represents the most comprehensive examination to date of this clinically important comorbidity. Dr. Caplan’s Take “This data reinforces what we observe clinically—depression and problematic [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) frequently travel together, requiring integrated assessment and treatment planning. The differentiation between psychiatric and community samples is particularly valuable for contextualizing prevalence in different clinical settings.” Clinical Perspective 🧠 Clinicians should routinely screen for depression when evaluating patients with cannabis use concerns and vice versa. This meta-analysis supports implementing standardized screening protocols for both conditions and developing integrated treatment pathways that address the bidirectional relationship rather than treating these conditions in isolation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20association%20between%20major%20depressive%20disorder%20and%20cannabis%20use%20disorder%3A%20A%20m...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41793962/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41793962/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20association%20between%20major%20depressive%20disorder%20and%20cannabis%20use%20disorder%3A%20A%20m...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41793962/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41793962/](https://pubmed.ncbi.nlm.nih.gov/41793962/) Table of Contents - [FAQ](#FAQ)[How common is major depression among patients with cannabis use disorder?](#How_common_is_major_depression_among_patients_with_cannabis_use_disorder) - [Should I screen patients with depression for cannabis use problems?](#Should_I_screen_patients_with_depression_for_cannabis_use_problems) - [Does the co-occurrence of depression and cannabis use disorder vary by treatment setting?](#Does_the_co-occurrence_of_depression_and_cannabis_use_disorder_vary_by_treatment_setting) - [What does this mean for treatment planning when both conditions are present?](#What_does_this_mean_for_treatment_planning_when_both_conditions_are_present) - [How reliable is this evidence for clinical decision-making?](#How_reliable_is_this_evidence_for_clinical_decision-making) - [Related](#Related) ## FAQ #### How common is major depression among patients with cannabis use disorder? This meta-analysis of over 3 million individuals found elevated rates of current major depressive disorder among people with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in both psychiatric and community settings. The bidirectional association suggests clinicians should routinely screen for depression in patients presenting with problematic cannabis use. #### Should I screen patients with depression for cannabis use problems? Yes, the study demonstrates a significant bidirectional relationship between major depressive disorder and cannabis use disorder. Patients with depression show increased prevalence of cannabis use disorder, making routine screening for substance use an important component of comprehensive depression care. #### Does the co-occurrence of depression and cannabis use disorder vary by treatment setting? The meta-analysis found differences between psychiatric and community samples, with subgroup analyses showing varying prevalence rates across settings. This suggests the [clinical context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) may influence the likelihood of identifying comorbid conditions, emphasizing the importance of comprehensive assessment regardless of setting. #### What does this mean for treatment planning when both conditions are present? The strong bidirectional association between MDD and CUD indicates these conditions frequently co-occur and may require integrated treatment approaches. Clinicians should consider addressing both conditions simultaneously rather than treating them in isolation, as untreated comorbidity may compromise outcomes for either condition. #### How reliable is this evidence for clinical decision-making? This meta-analysis included 55 studies with robust methodology following PRISMA guidelines and incorporated sensitivity analyses to assess study quality. The large sample size of over 3 million individuals and focus on current diagnoses makes this evidence highly relevant for contemporary clinical practice. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “The association between major depressive disorder and cannabis use disorder: A meta-analysis and meta-regression analysis.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41793962/”, “about”: “journal psychiatric research meta analysis association”, “isPartOf”: “Journal of psychiatric research”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Use Disorder Strongly Linked to Major Depression, New Review Finds](https://cedclinic.com/cannabis-use-disorder-strongly-linked-to-major-depression-new-review-finds/) A recent review highlights the strong link between cannabis use disorder and major depression, emphasizing the need for integrated clinical approaches. [Read the review](https://cedclinic.com/cannabis-use-disorder-strongly-linked-to-major-depression-new-review-finds/) [Huge study finds no evidence cannabis helps anxiety, depression, or PTSD | Catherine Adenle](https://cedclinic.com/cannabis-efficacy-mental-health-conditions-study/) This study challenges assumptions about [cannabis benefits](https://cedclinic.com/cannabis-and-sexuality-benefits-intimacy/) for mental health, providing critical insights for clinicians and patients. [Explore the study](https://cedclinic.com/cannabis-efficacy-mental-health-conditions-study/) [Two newly released analyses of existing research have found no evidence that marijuana is …](https://cedclinic.com/cannabis-efficacy-anxiety-depression-no-evidence/) Recent analyses question marijuana's efficacy for [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), underscoring the importance of evidence-based treatment. [Learn more](https://cedclinic.com/cannabis-efficacy-anxiety-depression-no-evidence/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).